A biodegradable nano-microparticle prime-boost vaccine strategy

可生物降解的纳米微粒初免-加强疫苗策略

• 批准号: 9241953
• 负责人: Rhoel David Ramos Dinglasan
• 金额: $ 30.67万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9241953
• 关键词: Adjuvant; Africa South of the Sahara; African; Agonist; Animal Model; Anopheles gambiae; Antibodies; Antibody Response; Antibody titer measurement; Antigen Targeting; Antigens; Back; Beds; Blocking Antibodies; CD4 Positive T Lymphocytes; Child; Communicable Diseases; Consensus; Country; Culicidae; Dendritic Cells; Development; Disease; Dose; Drug resistance; Encapsulated; Engineering; Exhibits; Formulation; Funding; Glycolic-Lactic Acid Polyester; Goals; Helper-Inducer T-Lymphocyte; Human; Hybrids; Immune response; Immune system; Immunization; Immunize; Immunologics; Individual; Ligands; Malaria; Malaria Vaccines; Methods; Midgut; Modeling; Mus; Ovalbumin; Parasites; Plasmodium falciparum; Polystyrenes; Preparation; Research Infrastructure; Research Personnel; Rodent; Rodent Model; Sheep; Surface; System; Technology; Toll-like receptors; United States National Institutes of Health; Vaccinated; Vaccination; Vaccine Antigen; Vaccines; Virus-like particle; Work; base; density; ethylene glycol; follow-up; global health; improved; killings; lymph nodes; malaria transmission-blocking vaccine; mathematical model; mouse model; nano; nanoparticle; next generation; prevent; public health relevance; targeted delivery; tool; trafficking; transmission process; transmission-blocking vaccine; uptake; vaccine delivery; vaccine development; vaccine efficacy; vector mosquito

DESCRIPTION (provided by applicant): Biodegradable nano- and microparticle technologies may offer safe, synergistic approaches for the multi-mode presentation of a vaccine antigen to the human immune system in a single formulation. Our proposal harnesses (1) the ability of virus-like nanoparticles to achieve a strong priming immune response, (2) the efficiency of biodegradable microparticles as slow-release "natural" boosting platforms, and (3) the capability of co-delivery of immunostimulatory agonists into a single platform for the development of the next generation of malaria transmission-blocking vaccines (TBVs). TBVs are considered one of the critical tools in the global effort to eliminate and eradicate malaria, since they function to block mosquito transmission of both drug- resistant and susceptible parasites from one individual to another. However, TBVs suffer from the lack of natural boosting, as the target antigens themselves are only present inside the mosquito, and the recent mathematical models for implementation suggest that the ideal vaccine development goal is a single immunization approach that is capable of eliciting high titer antibodies for over at least one year, but preferably more. To circumvent these TBV as well as general vaccine development concerns, we propose to engineer a "mixed mode" nano-/microparticle delivery system that leverages different attributes of lymph node (LN)- targeting biodegradable nanoparticles for effective presentation of the TBV antigen, AnAPN1, to dendritic cells (DC) and biodegradable microparticles for sustained release of AnAPN1 antigen to permit continued boosting, therefore inducing a superior immune response in the vaccinated individual. For our initial studies in a rodent model, we will develop size-controlled biodegradable LN-targeting nanoparticles for effective delivery and presentation of the AnAPN1 antigen to LN-resident DCs, followed by functional characterization of the AnAPN1-specific immune response. We will then engineer DC-activating nanoparticles to potentiate the antibody response to co-delivered AnAPN1 antigen followed by characterization of the effect of nanoparticle- delivered adjuvant on the functional AnAPN1-specific immune response. Lastly, we will construct a single-dose vaccine with DC-targeting biodegradable nanoparticles and AnAPN1-releasing microparticles and assess the durability and transmission-blocking efficacy of AnAPN1-specific antibodies in a large animal model.

描述（由申请人提供）：可生物降解的纳米和微粒技术可以提供安全、协同的方法，以单一配方将疫苗抗原多模式呈递到人体免疫系统。我们的建议利用了(1)病毒样纳米颗粒实现强启动免疫应答的能力，(2)可生物降解微颗粒作为缓释“天然”增强平台的效率，以及(3)将免疫刺激激动剂共同递送到开发下一代疟疾传播阻断疫苗（TBVs）的单一平台的能力。tvb被认为是全球消除和根除疟疾努力的关键工具之一，因为它们的作用是阻止耐药和易感寄生虫在个体之间的蚊子传播。然而，由于靶抗原本身只存在于蚊子体内，tbv缺乏自然增强，最近的实施数学模型表明，理想的疫苗开发目标是单一免疫方法，能够激发至少一年以上的高滴度抗体，但最好是更长时间。为了避免这些TBV以及一般疫苗开发问题，我们建议设计一种“混合模式”纳米/微粒递送系统，利用淋巴结（LN）靶向的可生物降解纳米颗粒的不同属性，有效地将TBV抗原AnAPN1呈递到树突状细胞（DC）和可生物降解微粒中，以持续释放AnAPN1抗原，从而在接种个体中诱导优越的免疫反应。在啮齿动物模型的初步研究中，我们将开发可控制大小的可生物降解的ln靶向纳米颗粒，用于将AnAPN1抗原有效地递送和呈递到ln居住的dc中，然后对AnAPN1特异性免疫反应进行功能表征。然后，我们将设计dc激活纳米颗粒来增强对共递送AnAPN1抗原的抗体反应，随后表征纳米颗粒递送佐剂对功能性AnAPN1特异性免疫反应的影响。最后，我们将利用靶向dc的可生物降解纳米颗粒和释放anapn1的微颗粒构建单剂量疫苗，并在大型动物模型中评估anapn1特异性抗体的持久性和传播阻断效果。